Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Enhance MD vs HumeCare+

Enhance MD
Site position #5

Higher grade

vs+26.2
HumeCare+
Site position #328

Lower grade

The verdict

Enhance MD takes it — 84.8/100 to 58.6/100.

Enhance MD grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. A transparently tiered compounded program — semaglutide $212/mo (first month $112), tirzepatide $280, a $169 microdose, and a $322 combo — backed by six-month lab testing and provider care, with NAD+ on the side.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEnhance MD +28
82
54
Dose & formulationEnhance MD +30
82
52
Clinical oversightEnhance MD +17
88
71
Labs & monitoringEnhance MD +37
90
53
FulfillmentEnhance MD +20
84
64
Contract termsEnhance MD +23
84
61
Enhance MD · left barHumeCare+ · right bar

The numbers

MetricEnhance MDHumeCare+
WeighScore84.8/10058.6/100
GradeBC
Site position#5#328
Semaglutide$249 every 4 weeks month-to-month (13 charges a year); $212/mo only on the 12-month prepay$199/mo (a floor, not a price: plus a separate fee at enrollment and every refill, non-refundable and never published; no dose stated, compounded)
Tirzepatide$329 every 4 weeks month-to-month (13 charges a year); $280/mo only on the 12-month prepay$299/mo (visible only after the medical intake; plus a separate fee at enrollment and every refill, never published; no dose stated, compounded)
CoverageNot publicly listedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Enhance MD

Site position #5 · B

Strengths

  • Transparent tiered pricing across sema, tirz, microdose, and combo
  • Dose-flat — the price does not step up as you titrate
  • Six-month lab testing plus provider-led care
  • NAD+ longevity adjacency available

Where it loses points

  • Compounded only — no brand-name Ozempic/Wegovy or Mounjaro/Zepbound
  • No oral or sublingual route
  • States served are not published
  • Higher entry price than the cheapest compounded programs
HumeCare+

Site position #328 · C

Strengths

  • Pairs compounded semaglutide with continuous body-composition tracking (lose fat, preserve muscle)
  • Includes a Hume Pod body-composition device at no extra cost
  • Billed monthly with no minimum term — the plan renews month to month and can be canceled before the renewal date, in a category full of three- and six-month prepays
  • Backed by Hume Health, an established body-composition scale brand
  • Clinician-prescribed and monitored with weekly tracking

Where it loses points

  • The advertised $199 is a floor rather than the price: its terms charge a non-refundable clinical consultation fee at enrollment AND at every refill, never state what that fee is, and add that dosages or formulations may carry further charges at the company's sole discretion
  • Final medication pricing is gated behind an intake quiz
  • Only semaglutide is shown on the marketing site (tirzepatide not confirmed)
  • Prescribing medical group and pharmacy partner not named
  • States of operation not published
  • LegitScript certification was not documented on the public pages reviewed

Featured provider

Enhance MD

Enhance MD scores 84.8/100 (B). A transparently tiered compounded program — semaglutide $212/mo (first month $112), tirzepatide $280, a $169 microdose, and a $322 combo — backed by six-month lab testing and provider care, with NAD+ on the side.

Commercial relationships affect this placement. The score comparison above is separate.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard